Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Adicet Bio Inc
ACET
Healthcare
Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the...
potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ACET)
New Post
View:
Posts & Comments
Threaded Posts
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jan 24, 2022 7:27am
7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST!
$ACET Adicet Bio (NASDAQ: ACET) is a biotechnology Company working on bringing allogeneic gamma delta T cell therapies for cancer and other therapies. The Company announced positive interim
...more
(14)
•••
yllanycrop
X
View Profile
View Bullboard History
Post by
yllanycrop
on Aug 16, 2020 3:16pm
really now
this has gone from $20 in 2018 to $2.31 now. I'm an old guy and would like to invest but if it's been too good to be true for years. why now??? any info would be appreciated glta
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA
posted Apr 25, 2024 9:00am by
Indiva Ltd
-
|
“Net Income was just shy of break-even in Q4, which is a testament to the popularity of our products, our industry leading low-cost production platform, and our focus on cost control. Our core brands, namely Pearls by Grön, No Future, Bhang Chocolate and Indiva Blips continue to gain market share in Canada, as Indiva continues to hold the #1 market share position in edibles nationally," said ...read more
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Dec 12, 2019 10:31am
still holding this stock
should be a breakout to the upside soon,so glta.
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Nov 18, 2019 10:13am
CASH over $100 Million,NO DEBT,FREE Company
what's not to like,the company could buy back all its shares with its cash position,so glta.
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Nov 18, 2019 9:40am
it's a buy today for me
was on my watchlist and it was way oversold.so glta.
(1)
•••
Diamfrank07
X
View Profile
View Bullboard History
Post by
Diamfrank07
on Nov 17, 2019 9:24pm
$1 a share.
Yes please. 100m in bank. This is severly undervalued.. $2 in the next few weeks. 100% gain. Thanks.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Stage Set for Creation of a Leading Intermediate Gold Producer
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study